phentermine and glucagon-like peptide 1

phentermine has been researched along with glucagon-like peptide 1 in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Nakazato, M; Ueno, H	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Acosta, A; Burton, D; Camilleri, M; Eckert, D; Iturrino, J; O'Neill, J; Shin, A; Vazquez-Roque, MI; Zinsmeister, AR	1
Fujioka, K	1

Reviews

5 review(s) available for phentermine and glucagon-like peptide 1

Article	Year
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015

Trials

1 trial(s) available for phentermine and glucagon-like peptide 1

Article	Year
Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology, 2015, Volume: 148, Issue:3 Topics: Adult; Aged; Anti-Obesity Agents; Anxiety; Body Image; Body Mass Index; Cholecystokinin; Cohort Studies; Delayed-Action Preparations; Depression; Dipeptides; Drug Combinations; Fasting; Female; Fructose; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Obesity; Organ Size; Overweight; Peptide YY; Phentermine; Postprandial Period; Principal Component Analysis; Prospective Studies; Satiation; Self Efficacy; Stomach; Topiramate; Treatment Outcome	2015

Article

Year

Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.

Gastroenterology, 2015, Volume: 148, Issue:3

Topics: Adult; Aged; Anti-Obesity Agents; Anxiety; Body Image; Body Mass Index; Cholecystokinin; Cohort Studies; Delayed-Action Preparations; Depression; Dipeptides; Drug Combinations; Fasting; Female; Fructose; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Obesity; Organ Size; Overweight; Peptide YY; Phentermine; Postprandial Period; Principal Component Analysis; Prospective Studies; Satiation; Self Efficacy; Stomach; Topiramate; Treatment Outcome

2015